These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 24015910)
1. Identification of a new class of glucokinase activators through structure-based design. Hinklin RJ; Boyd SA; Chicarelli MJ; Condroski KR; DeWolf WE; Lee PA; Lee W; Singh A; Thomas L; Voegtli WC; Williams L; Aicher TD J Med Chem; 2013 Oct; 56(19):7669-78. PubMed ID: 24015910 [TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-pyridylureas as glucokinase activators. Hinklin RJ; Aicher TD; Anderson DA; Baer BR; Boyd SA; Condroski KR; DeWolf WE; Kraser CF; McVean M; Rhodes SP; Sturgis HL; Voegtli WC; Williams L; Houze JB J Med Chem; 2014 Oct; 57(19):8180-6. PubMed ID: 25203462 [TBL] [Abstract][Full Text] [Related]
3. Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation. Wang Z; Shi X; Zhang H; Yu L; Cheng Y; Zhang H; Zhang H; Zhou J; Chen J; Shen X; Duan W Eur J Med Chem; 2017 Oct; 139():128-152. PubMed ID: 28800453 [TBL] [Abstract][Full Text] [Related]
4. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus. Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and SAR of novel glucokinase activators. Cheruvallath ZS; Gwaltney SL; Sabat M; Tang M; Feng J; Wang H; Miura J; Guntupalli P; Jennings A; Hosfield D; Lee B; Wu Y Bioorg Med Chem Lett; 2013 Apr; 23(7):2166-71. PubMed ID: 23434031 [TBL] [Abstract][Full Text] [Related]
7. Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients. Sarabu R; Bizzarro FT; Corbett WL; Dvorozniak MT; Geng W; Grippo JF; Haynes NE; Hutchings S; Garofalo L; Guertin KR; Hilliard DW; Kabat M; Kester RF; Ka W; Liang Z; Mahaney PE; Marcus L; Matschinsky FM; Moore D; Racha J; Radinov R; Ren Y; Qi L; Pignatello M; Spence CL; Steele T; Tengi J; Grimsby J J Med Chem; 2012 Aug; 55(16):7021-36. PubMed ID: 22809456 [TBL] [Abstract][Full Text] [Related]
8. Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator. Hinklin RJ; Baer BR; Boyd SA; Chicarelli MD; Condroski KR; DeWolf WE; Fischer J; Frank M; Hingorani GP; Lee PA; Neitzel NA; Pratt SA; Singh A; Sullivan FX; Turner T; Voegtli WC; Wallace EM; Williams L; Aicher TD Bioorg Med Chem; 2020 Jan; 28(1):115232. PubMed ID: 31818630 [TBL] [Abstract][Full Text] [Related]
9. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators. Vu CB; Bemis JE; Disch JS; Ng PY; Nunes JJ; Milne JC; Carney DP; Lynch AV; Smith JJ; Lavu S; Lambert PD; Gagne DJ; Jirousek MR; Schenk S; Olefsky JM; Perni RB J Med Chem; 2009 Mar; 52(5):1275-83. PubMed ID: 19199480 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators. Charaya N; Pandita D; Grewal AS; Lather V Comput Biol Chem; 2018 Apr; 73():221-229. PubMed ID: 29518630 [TBL] [Abstract][Full Text] [Related]
11. Discovery and hit-to-lead optimization of novel allosteric glucokinase activators. Lang M; Seifert MH; Wolf KK; Aschenbrenner A; Baumgartner R; Wieber T; Trentinaglia V; Blisse M; Tajima N; Yamashita T; Vitt D; Noda H Bioorg Med Chem Lett; 2011 Sep; 21(18):5417-22. PubMed ID: 21813277 [TBL] [Abstract][Full Text] [Related]
12. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963 [TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus. Fujieda H; Kogami M; Sakairi M; Kato N; Makino M; Takahashi N; Miyazawa T; Harada S; Yamashita T Eur J Med Chem; 2018 Aug; 156():269-294. PubMed ID: 30006171 [TBL] [Abstract][Full Text] [Related]
14. [Salicylic acid derivatives as simplified and novel GK small molecule activators]. Huo LC; Zhang YL; Lei L; Liu SN; Shen ZF; Wang YL; Song HR; Feng ZQ Yao Xue Xue Bao; 2013 Apr; 48(4):514-20. PubMed ID: 23833938 [TBL] [Abstract][Full Text] [Related]
15. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus. Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809 [TBL] [Abstract][Full Text] [Related]
16. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Matschinsky FM; Zelent B; Doliba NM; Kaestner KH; Vanderkooi JM; Grimsby J; Berthel SJ; Sarabu R Handb Exp Pharmacol; 2011; (203):357-401. PubMed ID: 21484579 [TBL] [Abstract][Full Text] [Related]